{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:55:16Z","timestamp":1791082516531,"version":"4.1.0"},"reference-count":226,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T00:00:00Z","timestamp":1463529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"name":"State of New Jersey Commission on Cancer Research","award":["05-2405-CCR-EO"],"award-info":[{"award-number":["05-2405-CCR-EO"]}]},{"name":"Pediatric AIDS Clinical Trials Group"},{"name":"NIH-NIAID (DoA)","award":["202PVCL05"],"award-info":[{"award-number":["202PVCL05"]}]},{"name":"NIH (BIRCWH)","award":["HD-1457"],"award-info":[{"award-number":["HD-1457"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI034552, AI060403"],"award-info":[{"award-number":["AI034552, AI060403"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foundation of UMDNJ"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0154842","type":"journal-article","created":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T17:50:19Z","timestamp":1463593819000},"page":"e0154842","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial"],"prefix":"10.1371","volume":"11","author":[{"given":"Deepti","family":"Saxena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Spino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Tricta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette M.","family":"Cracchiolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel-Rainer","family":"Hanauske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlene","family":"D\u2019Alliessi Gandolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Karn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsafi","family":"Pe\u2019ery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut M.","family":"Hanauske-Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,5,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1056\/NEJMra0706737","article-title":"The challenge of HIV-1 subtype diversity","volume":"358","author":"BS Taylor","year":"2008","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1128\/JVI.03576-12","article-title":"Variation of HIV-1 mutation spectra among cell types","volume":"87","author":"CM Holtz","year":"2013","journal-title":"J Virol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nm.3445","article-title":"HIV-1 persistence in CD4 T cells with stem cell-like properties","volume":"20","author":"MJ Buzon","year":"2014","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1086\/432916","article-title":"Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management","volume":"192","author":"AM Wensing","year":"2005","journal-title":"J Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/QAD.0b013e32834db418","article-title":"Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission","volume":"26","author":"JT Herbeck","year":"2012","journal-title":"AIDS"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1056\/NEJMc1405805","article-title":"Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation","volume":"371","author":"L Kordelas","year":"2014","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","author":"G Hutter","year":"2009","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2010-09-309591","article-title":"Evidence for the cure of HIV infection by CCR5Delta32\/Delta32 stem cell transplantation","volume":"117","author":"K Allers","year":"2011","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e1003347","DOI":"10.1371\/journal.ppat.1003347","article-title":"Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient","volume":"9","author":"SA Yukl","year":"2013","journal-title":"PLoS Pathog"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"P Tebas","year":"2014","journal-title":"N Engl J Med"},{"key":"ref11","unstructured":"Bureau of Disease Control, Prevention and Epidemiology HIV\/STD\/VH\/TB Epidemiology Section, Michigan Department of Community Health (2014) Annual review of HIV trends in southeast Michigan (2008\u20132012). Overall trends in new HIV diagnoses in southeast Michigan. pp 1\u20135. Available: http:\/\/www.michigan.gov\/documents\/mdch\/SEMI_withDet14_456015_7.pdf<\/ext-link>"},{"key":"ref12","unstructured":"Department of Health, HIV\/AIDS, Hepatitis, STD, and TB Administration, Government of the District of Columbia (2013) Annual Epidemiology & Surveillance Report 2012. pp 1\u201377. Available: http:\/\/doh.dc.gov\/sites\/default\/files\/dc\/sites\/doh\/publication\/attachments\/2013%20Annual%20Report%20FINAL-2.pdf<\/ext-link>"},{"key":"ref13","unstructured":"United States State Department (2014) PEPFAR\u2014The United States President's Emergency Plan for AIDS Relief\u2014Countries. Office of U.S. Global AIDS Coordinator and the Bureau of Public Affairs. Washington, DC Available: http:\/\/www.pepfar.gov\/countries\/index.htm<\/ext-link>"},{"key":"ref14","unstructured":"Reese M (2015) Declaration of Public Health Emergency in Scott County, Indiana (Executive Order 15\u201305). Executive Department Indianapolis\u2014State of Indiana. Available: http:\/\/www.in.gov\/activecalendar\/EventList.aspx?view=EventDetails&eventidn=214652&information_id=212487&type=&syndicate=syndicate<\/ext-link>"},{"key":"ref15","unstructured":"Maddox L, Bush T, Moise M (2015) Epidemiology of HIV infection\u2014Trends in Florida reported through 2014. Florida Department of Health, Division of Disease Control and Health Protection, HIV\/AIDS Section. Tallahassee, FL Available: http:\/\/www.floridahealth.gov\/diseases-and-conditions\/aids\/surveillance\/_documents\/hiv-aids-slide-sets\/2014\/state-trends-2014.pdf#search="hiv%202014"<\/ext-link>"},{"key":"ref16","unstructured":"Editorial (2015) Alarming rise in HIV cases. Tampa Bay Times, July 10, 2015. Tampa Bay, FL Available: http:\/\/www.tampabay.com\/opinion\/editorials\/editorial-alarming-rise-in-hiv-cases\/2236948<\/ext-link>"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection","volume":"373","author":"JD Lundgren","year":"2015","journal-title":"N Engl J Med"},{"key":"ref18","unstructured":"HHS Panel on Antiretroviral Guidelines for Adults and Adolescents (2015) Statement Regarding Results from the START and TEMPRANO Trials. U.S. Department of Health and Human Services, Office of AIDS Research Council. Available: https:\/\/aidsinfo.nih.gov\/news\/1592\/statement-from-adult-arv-guideline-panel---start-and-temprano-trials<\/ext-link>"},{"key":"ref19","unstructured":"World Health Organization (2015) Guideline on when to start antiretroviral therapy and on pre-exposure prophylasis for HIV. Geneva, Switzerland. Available: http:\/\/apps.who.int\/iris\/bitstream\/10665\/186275\/1\/9789241509565_eng.pdf<\/ext-link>"},{"key":"ref20","unstructured":"World Health Organization (2015) HIV \/ AIDS Factsheet No 360. Geneva, Switzerland. Available: http:\/\/www.who.int\/mediacentre\/factsheets\/fs360\/en\/<\/ext-link>"},{"key":"ref21","unstructured":"United States State Department (2015) PEPFAR\u2014Latest Results. Office of U.S. Global AIDS Coordinator and the Bureau of Public Affairs. Washington, DC Available: http:\/\/www.pepfar.gov\/documents\/organization\/189671.pdf<\/ext-link>"},{"key":"ref22","unstructured":"Joint United Nations Programme on HIV\/AIDS (2014) Children and HIV. Geneva, Switzerland. Available at: http:\/\/www.unaids.org\/en\/media\/unaids\/contentassets\/documents\/unaidspublication\/2014\/FactSheet_Children_en.pdf<\/ext-link>"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/QAD.0b013e32834dce6e","article-title":"Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults","volume":"26","author":"CE Sloan","year":"2012","journal-title":"AIDS"},{"key":"ref24","unstructured":"United States State Department (2015) PEPFAR Funding Fact Sheet Fiscal Years 2014\u20132016. Office of U.S. Global AIDS Coordinator and the Bureau of Public Affairs. Washington, DC Available: http:\/\/www.pepfar.gov\/documents\/organization\/189671.pdf<\/ext-link>"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1097\/QAD.0b013e328340a239","article-title":"Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication","volume":"24","author":"TW Chun","year":"2010","journal-title":"AIDS"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00002030-200301240-00009","article-title":"HIV RNA in plasma rebounds within days during structured treatment interruptions","volume":"17","author":"M Fischer","year":"2003","journal-title":"AIDS"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells","volume":"9","author":"JD Siliciano","year":"2003","journal-title":"Nat Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0006-2952(98)00053-7","article-title":"Antiretroviral effects of deoxyhypusyl hydroxylase inhibitors: a hypusine-dependent host cell mechanism for replication of human immunodeficiency virus type 1 (HIV-1)","volume":"55","author":"L Andrus","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0022-5193(82)90320-4","article-title":"A stereochemical concept for the catalytic mechanism of prolyl hydroxlyase. Applicability to classification and design of inhibitors","volume":"94","author":"HM Hanauske-Abel","year":"1982","journal-title":"J Theor Biol"},{"key":"ref30","unstructured":"Hanauske-Abel HM (1983) \u00dcber einen stereochemischen Vorschlag f\u00fcr den katalytischen Mechanismus der Prolylhydroxylase, seine Anwendung zur Klassifizierung und Formulierung von Hemmstoffen sowie die Entwicklung und Erprobung eines 'ma\u00dfgeschneiderten' neuartigen Inhibitors. Thesis, Department of Pharmacology and Toxicology, Philipps Universit\u00e4t, Marburg, Germany"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2174\/0929867033457601","article-title":"The HAG mechanism: a molecular rationale for the therapeutic application of iron chelators in human diseases involving the 2-oxoacid utilizing dioxygenases","volume":"10","author":"HM Hanauske-Abel","year":"2003","journal-title":"Curr Med Chem"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0167-4838(91)90053-3","article-title":"The active site of deoxyhypusyl hydroxylase: use of catecholpeptides and their component chelator and peptide moieties as molecular probes","volume":"1077","author":"A Abbruzzese","year":"1991","journal-title":"Biochim Biophys Acta"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1172\/JCI117684","article-title":"Specific inhibition of eIF-5A and collagen hydroxylation by a single agent. Antiproliferative and fibrosuppressive effects on smooth muscle cells from human coronary arteries","volume":"95","author":"TA McCaffrey","year":"1995","journal-title":"J Clin Invest"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1073\/pnas.0509348102","article-title":"Molecular cloning, expression, and structural prediction of deoxyhypusine hydroxylase: a HEAT-repeat-containing metalloenzyme","volume":"103","author":"JH Park","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1432-1033.1984.tb07907.x","article-title":"The 2-oxoglutarate binding site of prolyl 4-hydroxylase. Identification of distinct subsites and evidence for 2-oxoglutarate decarboxylation in a ligand reaction at the enzyme-bound ferrous ion","volume":"138","author":"K Majamaa","year":"1984","journal-title":"Eur J Biochem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1042\/bj2290127","article-title":"Differences between collagen hydroxylases and 2-oxoglutarate dehydrogenase in their inhibition by structural analogues of 2-oxoglutarate","volume":"229","author":"K Majamaa","year":"1985","journal-title":"Biochem J"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/bj2480625","article-title":"Pyridinedicarboxylates, the first mechanism-derived inhibitors for prolyl 4-hydroxylase, selectively suppress cellular hydroxyprolyl biosynthesis. Decrease in interstitial collagen and Clq secretion in cell culture","volume":"248","author":"G Tschank","year":"1987","journal-title":"Biochem J"},{"issue":"Suppl 3","key":"ref38","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/0168-8278(91)90003-T","article-title":"Prolyl 4-hydroxylase, a target enzyme for drug development. Design of suppressive agents and the in vitro effects of inhibitors and proinhibitors","volume":"13","author":"HM Hanauske-Abel","year":"1991","journal-title":"J Hepatol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1203\/00006450-199604001-00965","article-title":"Deferiprone, but not deferoxamine, inhibits biosynthesis of fibrillar procollagens in iron-overloaded thalassemic patients","volume":"39","author":"RS Newfield","year":"1996","journal-title":"Ped Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1203\/00006450-199604001-00966","article-title":"Deferiprone: An in vitro inhibitor of protein hydroxylases vital for matrix formation and cell proliferation","volume":"39","author":"RS Newfield","year":"1996","journal-title":"Ped Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ijc.10515","article-title":"The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro","volume":"100","author":"PM Clement","year":"2002","journal-title":"Int J Cancer"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"14738","DOI":"10.1073\/pnas.0604005103","article-title":"Direct spectroscopic detection of a C-H-cleaving high-spin Fe(IV) complex in a prolyl-4-hydroxylase","volume":"103","author":"LM Hoffart","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"e74414","DOI":"10.1371\/journal.pone.0074414","article-title":"Drug-Induced Reactivation of Apoptosis Abrogates HIV-1 Infection","volume":"8","author":"HM Hanauske-Abel","year":"2013","journal-title":"PLOS ONE"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/0014-5793(95)00493-S","article-title":"Detection of a sub-set of polysomal mRNAs associated with modulation of hypusine formation at the G1-S boundary. Proposal of a role for eIF-5A in onset of DNA replication","volume":"366","author":"HM Hanauske-Abel","year":"1995","journal-title":"FEBS Lett"},{"key":"ref45","unstructured":"Hanauske-Abel HM, Grady RW, Hanauske AR, Andrus L, Szabo P (1998) Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally infected cells. United States Patent 5,849,587."},{"key":"ref46","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1742-4690-6-90","article-title":"Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A","volume":"6","author":"M Hoque","year":"2009","journal-title":"Retrovirology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrd4090","article-title":"Phase II and Phase III attrition rates 2011\u20132012","volume":"12","author":"J Arrowsmith","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/483531a","article-title":"Drug development: Raise standards for preclinical cancer research","volume":"483","author":"CG Begley","year":"2012","journal-title":"Nature"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/clpt.1990.147","article-title":"Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one","volume":"48","author":"GJ Kontoghiorghes","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0166-3542(00)00084-X","article-title":"In vitro evaluation of the effect of temporary removal of HIV drug pressure","volume":"46","author":"M Witvrouw","year":"2000","journal-title":"Antiviral Res"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/095632020101200303","article-title":"Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses","volume":"12","author":"T Nitanda","year":"2001","journal-title":"Antivir Chem Chemother"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"17852","DOI":"10.1074\/jbc.273.28.17852","article-title":"HIV-1 Tat induces neuronal death via tumor necrosis factor-alpha and activation of non-N-methyl-D-aspartate receptors by a NFkappaB-independent mechanism","volume":"273","author":"DR New","year":"1998","journal-title":"J Biol Chem"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1136\/bjo.86.3.306","article-title":"Value of two mortality assessment techniques for organ cultured corneal endothelium: trypan blue versus TUNEL technique","volume":"86","author":"P Gain","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nm0295-129","article-title":"Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes","volume":"1","author":"TH Finkel","year":"1995","journal-title":"Nat Med"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.1002\/anie.200902130","article-title":"25 years after HIV discovery: prospects for cure and vaccine (Nobel lecture)","volume":"48","author":"L Montagnier","year":"2009","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-4690-5-19","article-title":"Apoptosis resistance in HIV-1 persistently-infected cells is independent of active viral replication and involves modulation of the apoptotic mitochondrial pathway","volume":"5","author":"PN Fernandez Larrosa","year":"2008","journal-title":"Retrovirology"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.virol.2008.03.015","article-title":"Human immunodeficiency virus (HIV-1) infection selectively downregulates PD-1 expression in infected cells and protects the cells from early apoptosis in vitro and in vivo","volume":"376","author":"NJ Venkatachari","year":"2008","journal-title":"Virology"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1742-4690-6-18","article-title":"HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression","volume":"6","author":"Z Klase","year":"2009","journal-title":"Retrovirology"},{"issue":"Suppl 1","key":"ref59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1365-2362.2002.0320s1091.x","article-title":"Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis","volume":"32","author":"NA Georgiou","year":"2002","journal-title":"Eur J Clin Invest"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/jcp.22100","article-title":"Apoptosis induction by eIF5A1 involves activation of the intrinsic mitochondrial pathway","volume":"223","author":"Z Sun","year":"2010","journal-title":"J Cell Physiol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"13737","DOI":"10.1038\/srep13737","article-title":"Secreted tyrosine sulfated-eIF5A mediates oxidative stress-induced apoptosis","volume":"5","author":"Y Seko","year":"2015","journal-title":"Sci Rep"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0003-2697(90)90004-S","article-title":"High-performance liquid chromatographic method for determination of hypusine and deoxyhypusine","volume":"184","author":"S Beninati","year":"1990","journal-title":"Anal Biochem"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"10829","DOI":"10.1073\/pnas.91.23.10829","article-title":"Induced gene expression of the hypusine-containing protein eukaryotic initiation factor 5A in activated human T lymphocytes","volume":"91","author":"D Bevec","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.4049\/jimmunol.0803222","article-title":"Microarray Analysis of Lymphatic Tissue Reveals Stage-Specific, Gene Expression Signatures in HIV-1 Infection","volume":"183","author":"Q Li","year":"2009","journal-title":"The Journal of Immunology"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1095\/biolreprod.106.051870","article-title":"ECC-1 cells: a well-differentiated steroid-responsive endometrial cell line with characteristics of luminal epithelium","volume":"75","author":"B Mo","year":"2006","journal-title":"Biol Reprod"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1086\/600867","article-title":"Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety","volume":"200","author":"PM Mesquita","year":"2009","journal-title":"J Infect Dis"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"e9310","DOI":"10.1371\/journal.pone.0009310","article-title":"In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide","volume":"5","author":"LC Rohan","year":"2010","journal-title":"PLoS One"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"e35654","DOI":"10.1371\/journal.pone.0035654","article-title":"Uterine epithelial cells specifically induce interferon-stimulated genes in response to polyinosinic-polycytidylic acid independently of estradiol","volume":"7","author":"MV Patel","year":"2012","journal-title":"PLoS One"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"e1000852","DOI":"10.1371\/journal.ppat.1000852","article-title":"Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation","volume":"6","author":"A Nazli","year":"2010","journal-title":"PLoS Pathog"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0166-3542(96)00946-1","article-title":"Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells","volume":"31","author":"M Okamoto","year":"1996","journal-title":"Antiviral Res"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1073\/pnas.92.12.5470","article-title":"Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives)","volume":"92","author":"J Balzarini","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1089\/088922201753342031","article-title":"Rapid alternation of drug therapy is highly efficient in suppressing the emergence of mutant drug-resistant HIV strains in cell culture","volume":"17","author":"J Balzarini","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"15109","DOI":"10.1073\/pnas.96.26.15109","article-title":"HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression","volume":"96","author":"RT Davey Jr.","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref74","unstructured":"National Department of Health, Republic of South Africa (2010) Clinical guidelines for the management of HIV & AIDS in adults and adolescents. pp. 1\u201342. Available: http:\/\/www.sahivsoc.org\/upload\/documents\/Clinical_Guidelines_for_the_Management_of_HIV_AIDS_in_Adults_Adolescents_2010.pdf<\/ext-link>"},{"key":"ref75","unstructured":"European Medicines Agency (2013) Ferriprox \u2122<\/sup>: Annex I\u2014Summary of product characteristics. pp 1\u201356. Available: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000236\/human_med_000789.jsp&mid=WC0b01ac058001d124<\/ext-link> http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000236\/WC500022050.pdf<\/ext-link>"},{"key":"ref76","unstructured":"Food and Drug Administration (2011) Oncologic Drugs Advisory Committee Briefing Document: NDA # 21\u2013825, Ferriprox\u00ae<\/sup> (deferiprone). pp 1\u20137. Available: http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/oncologicdrugsadvisorycommittee\/ucm271538.pdf<\/ext-link>"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/87979","article-title":"A quantitative assay for HIV DNA integration in vivo","volume":"7","author":"SL Butler","year":"2001","journal-title":"Nat Med"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"YC Ho","year":"2013","journal-title":"Cell"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.patbio.2014.07.007","article-title":"Quantification of viral DNA during HIV-1 infection: A review of relevant clinical uses and laboratory methods","volume":"63","author":"EK Alidjinou","year":"2015","journal-title":"Pathol Biol (Paris)"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"A Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1365-2125.2008.03103.x","article-title":"UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers","volume":"65","author":"LM Limenta","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/dmd.108.023101","article-title":"Deferiprone glucuronidation by human tissues and recombinant UDP-glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants","volume":"37","author":"MO Benoit-Biancamano","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/bcp.12473","article-title":"Population pharmacokinetics of deferiprone in healthy subjects","volume":"78","author":"F Bellanti","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"ref84","unstructured":"Center for Drug Evaluation and Research, Food and Drug Administration, United States Department of Health and Human Services (2003) Guidance for Industry. Exposure-Response Relationships\u2014Study Design, Data Analysis, and Regulatory Applications. April 2003 ed. pp. 1\u201328. Available at: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm072109.pdf<\/ext-link>"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/infdis\/174.1.191","article-title":"Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection","volume":"174","author":"JM Raboud","year":"1996","journal-title":"J Infect Dis"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/infdis\/175.2.247","article-title":"Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group","volume":"175","author":"WB Paxton","year":"1997","journal-title":"J Infect Dis"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1097\/QAD.0b013e328312c756","article-title":"Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression","volume":"22","author":"K Modjarrad","year":"2008","journal-title":"AIDS"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nm0696-625","article-title":"HIV viral load markers in clinical practice","volume":"2","author":"MS Saag","year":"1996","journal-title":"Nat Med"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1212\/01.WNL.0000129990.32253.7B","article-title":"The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease","volume":"63","author":"C Holmes","year":"2004","journal-title":"Neurology"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3109\/03009749609069987","article-title":"Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis","volume":"25","author":"PC Gotzsche","year":"1996","journal-title":"Scand J Rheumatol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/art.20697","article-title":"Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis","volume":"51","author":"J Cibere","year":"2004","journal-title":"Arthritis Rheum"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/1535-7163.MCT-06-0249","article-title":"The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents","volume":"6","author":"WM Stadler","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0895-4356(93)90163-U","article-title":"Randomized discontinuation trials: utility and efficiency","volume":"46","author":"JA Kopec","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/00031305.2012.720900","article-title":"Estimation of progression-free survival for all treated patients in the randomized discontinuation trial design","volume":"66","author":"TG Karrison","year":"2012","journal-title":"Am Statistician"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1128\/JVI.76.3.968-979.2002","article-title":"Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection","volume":"76","author":"SD Frost","year":"2002","journal-title":"J Virol"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"F59","DOI":"10.1097\/00002030-199905280-00001","article-title":"Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy","volume":"13","author":"PR Harrigan","year":"1999","journal-title":"AIDS"},{"key":"ref97","unstructured":"National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS (2009) Table for grading the severity of adult and pediatric adverse events, version 1.0 of December 2004 with clarification of August 2009. Available: http:\/\/rsc.tech-res.com\/Document\/safetyandpharmacovigilance\/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf<\/ext-link>"},{"key":"ref98","unstructured":"National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases (2007) Adult Toxicity Table. Available: http:\/\/www.niaid.nih.gov\/LabsAndResources\/resources\/DMIDClinRsrch\/Documents\/dmidadulttox.pdf<\/ext-link>"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jacc.2005.08.067","article-title":"Prolonged QTc interval and risk of sudden cardiac death in a population of older adults","volume":"47","author":"SM Straus","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"ref100","unstructured":"Center for Drug Evaluation and Research, Food and Drug Administration, United States Department of Health and Human Services (2005) Guidance for Industry\u2014Clinical Evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. pp 1\u201316. Available: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm073153.pdf<\/ext-link>"},{"key":"ref101","unstructured":"Center for Drug Evaluation and Research, Food and Drug Administration, United States Department of Health and Human Services (2009) Guidance for Industry\u2014Antiviral Product Development\u2014Conducting and Submitting Virology Studies to the Agency. pp 1\u201314. Available at: http:\/\/www.fda.gov\/OHRMS\/DOCKETS\/98fr\/05d-0183-gdl0002-01.pdf<\/ext-link>"},{"key":"ref102","unstructured":"Committee for Medicinal Products for Human Use, European Medicines Agency (2013) Guideline on the clinical development of medicinal products for the treatment of HIV infection. pp. 1\u201318. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2013\/09\/WC500150733.pdf<\/ext-link>"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1248\/yakushi1947.90.10_1222","article-title":"Syntheses of N-substituted-3-glucosyloxy-2-methyl-4-pyridones and their aglycones","volume":"90","author":"M Yasue","year":"1970","journal-title":"Yakugaku Zasshi"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(85)91472-2","article-title":"New orally active iron chelators","volume":"1","author":"GJ Kontoghiorghes","year":"1985","journal-title":"Lancet"},{"key":"ref105","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"C Borgna-Pignatti","year":"2004","journal-title":"Haematologica"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood-2007-07-102335","article-title":"Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications","volume":"111","author":"YS Sohn","year":"2008","journal-title":"Blood"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bcmd.2009.01.002","article-title":"Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies","volume":"42","author":"A Maggio","year":"2009","journal-title":"Blood Cells Mol Dis"},{"key":"ref108","first-page":"489","article-title":"Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis","volume":"88","author":"A Piga","year":"2003","journal-title":"Haematologica"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2005-07-2933","article-title":"Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major","volume":"107","author":"C Borgna-Pignatti","year":"2006","journal-title":"Blood"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.2009.019042","article-title":"Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging","volume":"96","author":"A Pepe","year":"2011","journal-title":"Haematologica"},{"key":"ref111","first-page":"1187","article-title":"Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980\u20132004","volume":"91","author":"P Telfer","year":"2006","journal-title":"Haematologica"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1532-429X-10-42","article-title":"Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance","volume":"10","author":"B Modell","year":"2008","journal-title":"J Cardiovasc Magn Reson"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1124\/dmd.105.004879","article-title":"Isoform-specific expression and induction of UDP-glucuronosyltransferase in immunoactivated peritoneal macrophages of the rat","volume":"33","author":"Y Tochigi","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1086\/507043","article-title":"Inhibition of multidrug-resistant HIV-1 by interference with cellular S-adenosylmethionine decarboxylase activity","volume":"194","author":"B Sch\u00e4fer","year":"2006","journal-title":"J Infect Dis"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1172\/JCI200521949","article-title":"Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy","volume":"115","author":"I Hauber","year":"2005","journal-title":"J Clin Invest"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/cmdc.201300481","article-title":"In silico design, synthesis, and screening of novel deoxyhypusine synthase inhibitors targeting HIV-1 replication","volume":"9","author":"M Schroeder","year":"2014","journal-title":"ChemMedChem"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF02255534","article-title":"Antihuman Immunodeficiency Virus (HIV-1) Activities of Inhibitors of Polyamine Pathways","volume":"3","author":"PK Chiang","year":"1996","journal-title":"J Biomed Sci"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"11176","DOI":"10.1128\/JVI.01692-15","article-title":"Inhibition of HIV expression and integration in macrophages by methylglyoxal-bis-guanylhydrazone","volume":"89","author":"X Jin","year":"2015","journal-title":"J Virol"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1046\/j.1432-1033.2003.03726.x","article-title":"Anti-HIV-1 activity of 3-deaza-adenosine analogs. Inhibition of S-adenosylhomocysteine hydrolase and nucleotide congeners","volume":"270","author":"RK Gordon","year":"2003","journal-title":"Eur J Biochem"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1073\/pnas.92.1.215","article-title":"Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: increased potency against 3'-azido-3'-deoxythymidine-resistant HIV-1 strains","volume":"92","author":"DL Mayers","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1021\/jm0201621","article-title":"Synthesis and evaluation of analogues of 5'-([(Z)-4-amino-2-butenyl]methylamino)-5'-deoxyadenosine as inhibitors of tumor cell growth, trypanosomal growth, and HIV-1 infectivity","volume":"45","author":"CJ Marasco Jr.","year":"2002","journal-title":"J Med Chem"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cyto.990120105","article-title":"A new class of reversible cell cycle inhibitors","volume":"12","author":"BD Hoffman","year":"1991","journal-title":"Cytometry"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cyto.990120306","article-title":"Mimosine reversibly arrests cell cycle progression at the G1-S phase border","volume":"12","author":"PA Watson","year":"1991","journal-title":"Cytometry"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0167-4889(94)90003-5","article-title":"Inhibition of the G1-S transition of the cell cycle by inhibitors of deoxyhypusine hydroxylation","volume":"1221","author":"HM Hanauske-Abel","year":"1994","journal-title":"Biochim Biophys Acta"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.str.2015.03.002","article-title":"Crystal Structure of the Peroxo-diiron(III) Intermediate of Deoxyhypusine Hydroxylase, an Oxygenase Involved in Hypusination","volume":"23","author":"Z Han","year":"2015","journal-title":"Structure"},{"key":"ref126","first-page":"35","article-title":"The pharmacological basis of therapeutics","author":"EM Ross","year":"1985"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"8031","DOI":"10.1073\/pnas.1402732111","article-title":"Iron chaperones PCBP1 and PCBP2 mediate the metallation of the dinuclear iron enzyme deoxyhypusine hydroxylase","volume":"111","author":"AG Frey","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/0008-5472.CAN-13-0474","article-title":"Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation","volume":"74","author":"E M\u00e9min","year":"2013","journal-title":"Cancer Res"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.23640","article-title":"Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies","volume":"89","author":"MD Minden","year":"2014","journal-title":"Am J Hematol"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.1158\/0008-5472.CAN-14-1031","article-title":"A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer","volume":"74","author":"K Fujimura","year":"2014","journal-title":"Cancer Res"},{"key":"ref131","unstructured":"Park MH, Clement PM, Hanauske-Abel HM, Wolff EC, Kleinman HK, Cracchiolo BM (2006) Methods of inhibiting formation of vascular channels and methods of inhibiting proliferation. United States Patent 7,141,589"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"e33138","DOI":"10.1371\/journal.pone.0033138","article-title":"A unique modification of the eukaryotic initiation factor 5A shows the presence of the complete hypusine pathway in Leishmania donovani","volume":"7","author":"B Chawla","year":"2012","journal-title":"PLoS One"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"e58318","DOI":"10.1371\/journal.pone.0058318","article-title":"Deoxyhypusine hydroxylase from Plasmodium vivax, the neglected human malaria parasite: molecular cloning, expression and specific inhibition by the 5-LOX inhibitor zileuton","volume":"8","author":"VA Atemnkeng","year":"2013","journal-title":"PLoS One"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/373117a0","article-title":"Viral dynamics in human immunodeficiency virus type 1 infection","volume":"373","author":"X Wei","year":"1995","journal-title":"Nature"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1126\/science.8096089","article-title":"High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR","volume":"259","author":"M Piatak Jr.","year":"1993","journal-title":"Science"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.qai.0000181281.75670.56","article-title":"HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss","volume":"40","author":"J Sch\u00fcpbach","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/infdis\/158.5.1132","article-title":"Rapid rebound of serum human immunodeficiency virus antigen after discontinuing zidovudine therapy","volume":"158","author":"JB Spear","year":"1988","journal-title":"J Infect Dis"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00042560-199510020-00005","article-title":"Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared","volume":"10","author":"JC Kappes","year":"1995","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"189","DOI":"10.7326\/0003-4819-110-3-189","article-title":"Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study","volume":"110","author":"TC Merigan","year":"1989","journal-title":"Ann Intern Med"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1097\/00002030-200007280-00003","article-title":"Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication","volume":"14","author":"JP Ioannidis","year":"2000","journal-title":"AIDS"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"F79","DOI":"10.1097\/00002030-199907300-00002","article-title":"Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy","volume":"13","author":"F Garcia","year":"1999","journal-title":"AIDS"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1172\/JCI7371","article-title":"HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy","volume":"104","author":"GM Ortiz","year":"1999","journal-title":"J Clin Invest"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2141.2000.01866.x","article-title":"Safety profile of the oral iron chelator deferiprone: a multicentre study","volume":"108","author":"AR Cohen","year":"2000","journal-title":"Br J Haematol"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/asheducation-2010.1.451","article-title":"Update on iron chelators in thalassemia","volume":"2010","author":"EJ Neufeld","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref145","unstructured":"Hanauske-Abel HM, McCaffrey TA, Grady RW (1998) Method for the treatment of fibroproliferative disorders by the application of inhibitors of protein hydroxylation. United States Patent 5,789,426"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1006\/bbrc.2000.3056","article-title":"Adenine-induced selective apoptosis toward HIV chronically infected cells in vitro","volume":"273","author":"K Hirasawa","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1371\/journal.ppat.0030134","article-title":"Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein","volume":"3","author":"S Swingler","year":"2007","journal-title":"PLoS Pathog"},{"key":"ref148","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1073\/pnas.261711499","article-title":"Motexafin gadolinium (Gd-Tex) selectively induces apoptosis in HIV-1 infected CD4+ T helper cells","volume":"99","author":"OD Perez","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref149","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1742-6405-7-7","article-title":"Inhibition of human immunodeficiency virus type-1 by cdk inhibitors","volume":"7","author":"I Guendel","year":"2010","journal-title":"AIDS Res Ther"},{"key":"ref150","doi-asserted-by":"crossref","first-page":"8207","DOI":"10.1074\/jbc.M606324200","article-title":"Identifying the membrane proteome of HIV-1 latently infected cells","volume":"282","author":"R Berro","year":"2007","journal-title":"J Biol Chem"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/4710","article-title":"Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein","volume":"5","author":"AM Vocero-Akbani","year":"1999","journal-title":"Nat Med"},{"key":"ref152","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/gt.2010.53","article-title":"Development of a nonintegrating Rev-dependent lentiviral vector carrying diphtheria toxin A chain and human TRAF6 to target HIV reservoirs","volume":"17","author":"Z Wang","year":"2010","journal-title":"Gene Ther"},{"key":"ref153","first-page":"180","article-title":"Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice","volume":"13","author":"A Imaz","year":"2011","journal-title":"AIDS Rev"},{"key":"ref154","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/QAI.0b013e318298a309","article-title":"Five-year trends in antiretroviral usage and drug costs in HIV-infected children in Thailand","volume":"64","author":"I Collins","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref155","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3851\/IMP2437","article-title":"Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review","volume":"18","author":"KM Stadeli","year":"2013","journal-title":"Antivir Ther"},{"key":"ref156","doi-asserted-by":"crossref","first-page":"e21048","DOI":"10.1371\/journal.pone.0021048","article-title":"Long-term costs and health impact of continued global fund support for antiretroviral therapy","volume":"6","author":"J Stover","year":"2011","journal-title":"PLoS One"},{"key":"ref157","doi-asserted-by":"crossref","first-page":"e1004000","DOI":"10.1371\/journal.pgen.1004000","article-title":"Loss and recovery of genetic diversity in adapting populations of HIV","volume":"10","author":"PS Pennings","year":"2014","journal-title":"PLoS Genet"},{"key":"ref158","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0140-6736(91)92651-H","article-title":"Lack of effect of desferrioxamine on in-vitro HIV-1 replication","volume":"338","author":"JK Lazdins","year":"1991","journal-title":"Lancet"},{"key":"ref159","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00042560-199808150-00009","article-title":"Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients","volume":"18","author":"Y Salhi","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/CMR.8.2.200","article-title":"Antiviral therapy for human immunodeficiency virus infections","volume":"8","author":"E De Clercq","year":"1995","journal-title":"Clin Microbiol Rev"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1742-4690-2-20","article-title":"Therapeutic targets for HIV-1 infection in the host proteome","volume":"2","author":"WS Liang","year":"2005","journal-title":"Retrovirology"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1517\/14712598.2011.540564","article-title":"Analysis of the roles of HIV-derived microRNAs","volume":"11","author":"A Narayanan","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1517\/14712590903257781","article-title":"Novel HIV-1 therapeutics through targeting altered host cell pathways","volume":"9","author":"W Coley","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"ref164","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/35023595","article-title":"Hsp27 negatively regulates cell death by interacting with cytochrome c","volume":"2","author":"JM Bruey","year":"2000","journal-title":"Nat Cell Biol"},{"key":"ref165","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1006\/viro.1997.8618","article-title":"Modulation of stress protein (hsp27 and hsp70) expression in CD4+ lymphocytic cells following acute infection with human immunodeficiency virus type-1","volume":"233","author":"Z Wainberg","year":"1997","journal-title":"Virology"},{"key":"ref166","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/sj.cdd.4400822","article-title":"Biochemical mechanisms of HIV induced T cell apoptosis","volume":"8","author":"N Selliah","year":"2001","journal-title":"Cell Death Differ"},{"key":"ref167","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1172\/JCI22954","article-title":"Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor","volume":"115","author":"JG Weaver","year":"2005","journal-title":"J Clin Invest"},{"key":"ref168","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd3137","article-title":"Targeting mitochondria for cancer therapy","volume":"9","author":"S Fulda","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"ref169","doi-asserted-by":"crossref","first-page":"E3281","DOI":"10.1073\/pnas.1303669110","article-title":"Inhibition of pluripotent stem cell-derived teratoma formation by small molecules","volume":"110","author":"MO Lee","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref170","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.7973634","article-title":"Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication","volume":"266","author":"F Lori","year":"1994","journal-title":"Science"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(97)24035-3","article-title":"Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide","volume":"350","author":"J Vila","year":"1997","journal-title":"Lancet"},{"key":"ref172","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1056\/NEJM199905273402114","article-title":"Control of HIV despite the discontinuation of antiretroviral therapy","volume":"340","author":"J Lisziewicz","year":"1999","journal-title":"N Engl J Med"},{"key":"ref173","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0140-6736(98)24029-3","article-title":"HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor","volume":"352","author":"J Lisziewicz","year":"1998","journal-title":"Lancet"},{"key":"ref174","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1089\/088922299310034","article-title":"Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters","volume":"15","author":"F Lori","year":"1999","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref175","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.exphem.2012.10.013","article-title":"Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients","volume":"41","author":"A Amaru Calzada","year":"2013","journal-title":"Exp Hematol"},{"key":"ref176","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3171\/jns.1997.86.5.0845","article-title":"Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway","volume":"86","author":"UM Schrell","year":"1997","journal-title":"J Neurosurg"},{"key":"ref177","doi-asserted-by":"crossref","first-page":"11569","DOI":"10.1021\/bi00094a013","article-title":"Reduction and loss of the iron center in the reaction of the small subunit of mouse ribonucleotide reductase with hydroxyurea","volume":"32","author":"S Nyholm","year":"1993","journal-title":"Biochemistry"},{"key":"ref178","doi-asserted-by":"crossref","first-page":"48814","DOI":"10.1074\/jbc.M109551200","article-title":"Structure-function investigation of the interaction of 1- and 2-substituted 3-hydroxypyridin-4-ones with 5-lipoxygenase and ribonucleotide reductase","volume":"276","author":"R Kayyali","year":"2001","journal-title":"J Biol Chem"},{"key":"ref179","doi-asserted-by":"crossref","first-page":"15265","DOI":"10.1073\/pnas.1310642110","article-title":"Distinct XPPX sequence motifs induce ribosome stalling, which is rescued by the translation elongation factor EF-P","volume":"110","author":"L Peil","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref180","doi-asserted-by":"crossref","first-page":"34809","DOI":"10.1074\/jbc.M109.039040","article-title":"Genetic identification of nascent peptides that induce ribosome stalling","volume":"284","author":"DR Tanner","year":"2009","journal-title":"J Biol Chem"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"10711","DOI":"10.1093\/nar\/gku768","article-title":"Translational stalling at polyproline stretches is modulated by the sequence context upstream of the stall site","volume":"42","author":"AL Starosta","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"ref182","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.cell.2011.10.002","article-title":"Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes","volume":"147","author":"NT Ingolia","year":"2011","journal-title":"Cell"},{"key":"ref183","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/nature08925","article-title":"Real-time tRNA transit on single translating ribosomes at codon resolution","volume":"464","author":"S Uemura","year":"2010","journal-title":"Nature"},{"key":"ref184","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrm3457","article-title":"Surveillance pathways rescuing eukaryotic ribosomes lost in translation","volume":"13","author":"M Graille","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref185","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nsmb.2057","article-title":"Structure of the no-go mRNA decay complex Dom34-Hbs1 bound to a stalled 80S ribosome","volume":"18","author":"T Becker","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"ref186","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molcel.2013.04.021","article-title":"eIF5A promotes translation of polyproline motifs","volume":"51","author":"E Gutierrez","year":"2013","journal-title":"Mol Cell"},{"key":"ref187","article-title":"Numbering Positions in HIV Relative to HXB2CG","author":"BT Korber","year":"2014","journal-title":"Numbering Positions in HIV Relative to HXB2CG"},{"key":"ref188","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1742-4690-9-47","article-title":"Overlapping effector interfaces define the multiple functions of the HIV-1 Nef polyproline helix","volume":"9","author":"LS Kuo","year":"2012","journal-title":"Retrovirology"},{"key":"ref189","doi-asserted-by":"crossref","first-page":"15718","DOI":"10.1074\/jbc.M114.572099","article-title":"The accessory factor Nef links HIV-1 to Tec\/Btk kinases in an Src homology 3 domain-dependent manner","volume":"289","author":"S Tarafdar","year":"2014","journal-title":"J Biol Chem"},{"key":"ref190","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0014-5793(99)01288-0","article-title":"Conservation of the central proline-rich (PxxP) motifs of human immunodeficiency virus type 1 Nef protein during the disease progression in two hemophiliac patients","volume":"459","author":"K Asamitsu","year":"1999","journal-title":"FEBS Lett"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.virol.2008.04.017","article-title":"The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation","volume":"377","author":"JP Donahue","year":"2008","journal-title":"Virology"},{"key":"ref192","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1006\/viro.1999.0178","article-title":"Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication","volume":"268","author":"T Fitzon","year":"2000","journal-title":"Virology"},{"key":"ref193","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0092-8674(01)00506-2","article-title":"Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding","volume":"107","author":"JE Garrus","year":"2001","journal-title":"Cell"},{"key":"ref194","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.coviro.2013.03.009","article-title":"Viral precursor polyproteins: keys of regulation from replication to maturation","volume":"3","author":"SA Yost","year":"2013","journal-title":"Curr Opin Virol"},{"key":"ref195","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1128\/JVI.61.12.3769-3773.1987","article-title":"Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine","volume":"61","author":"MS Smith","year":"1987","journal-title":"J Virol"},{"key":"ref196","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1128\/AAC.37.4.875","article-title":"Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides","volume":"37","author":"RF Schinazi","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"ref197","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/aid.1998.14.249","article-title":"Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1","volume":"14","author":"H Jonckheere","year":"1998","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref198","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1128\/AAC.39.5.1087","article-title":"Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates","volume":"39","author":"JW Mellors","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"ref199","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1128\/AAC.47.6.1805-1817.2003","article-title":"Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors","volume":"47","author":"M Niewerth","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"ref200","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.2165\/11538110-000000000-00000","article-title":"Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent","volume":"70","author":"A Subissi","year":"2010","journal-title":"Drugs"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1471-4914(02)02280-3","article-title":"Molecular basis of resistance to azole antifungals","volume":"8","author":"A Lupetti","year":"2002","journal-title":"Trends Mol Med"},{"key":"ref202","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1567-1364.2006.00188.x","article-title":"An atypical active cell death process underlies the fungicidal activity of ciclopirox olamine against the yeast Saccharomyces cerevisiae","volume":"7","author":"B Almeida","year":"2007","journal-title":"FEMS Yeast Res"},{"key":"ref203","doi-asserted-by":"crossref","first-page":"e53785","DOI":"10.1371\/journal.pone.0053785","article-title":"Proline: the distribution, frequency, positioning, and common functional roles of proline and polyproline sequences in the human proteome","volume":"8","author":"AA Morgan","year":"2013","journal-title":"PLoS One"},{"key":"ref204","doi-asserted-by":"crossref","first-page":"200","DOI":"10.5607\/en.2013.22.3.200","article-title":"4-hydroxy-2(E)-Nonenal facilitates NMDA-Induced Neurotoxicity via Triggering Mitochondrial Permeability Transition Pore Opening and Mitochondrial Calcium Overload","volume":"22","author":"IY Choi","year":"2013","journal-title":"Exp Neurobiol"},{"key":"ref205","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.freeradbiomed.2012.04.020","article-title":"Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retina","volume":"53","author":"D Song","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"ref206","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ijc.1308","article-title":"8-Cl-cAMP induces cell cycle-specific apoptosis in human cancer cells","volume":"93","author":"SN Kim","year":"2001","journal-title":"Int J Cancer"},{"key":"ref207","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1038\/sj.onc.1201899","article-title":"p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage","volume":"16","author":"N Bissonnette","year":"1998","journal-title":"Oncogene"},{"key":"ref208","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1523\/JNEUROSCI.17-04-01256.1997","article-title":"G1\/S cell cycle blockers and inhibitors of cyclin-dependent kinases suppress camptothecin-induced neuronal apoptosis","volume":"17","author":"DS Park","year":"1997","journal-title":"J Neurosci"},{"key":"ref209","doi-asserted-by":"crossref","first-page":"6654","DOI":"10.1128\/MCB.16.12.6654","article-title":"Protective role of p21(Waf1\/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells","volume":"16","author":"M Gorospe","year":"1996","journal-title":"Mol Cell Biol"},{"key":"ref210","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1523\/JNEUROSCI.16-03-01150.1996","article-title":"Cell cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support","volume":"16","author":"SE Farinelli","year":"1996","journal-title":"J Neurosci"},{"issue":"Suppl 2","key":"ref211","first-page":"S45","article-title":"Ligand-induced apoptosis of mature T lymphocytes (propriocidal regulation) occurs at distinct stages of the cell cycle","volume":"7","author":"SA Boehme","year":"1993","journal-title":"Leukemia"},{"key":"ref212","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/eji.1830230724","article-title":"Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle","volume":"23","author":"SA Boehme","year":"1993","journal-title":"Eur J Immunol"},{"key":"ref213","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1167\/iovs.10-6207","article-title":"The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration","volume":"52","author":"M Hadziahmetovic","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref214","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1107729108","article-title":"Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule","volume":"108","author":"L Josefsson","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref215","doi-asserted-by":"crossref","first-page":"e1003587","DOI":"10.1371\/journal.ppat.1003587","article-title":"Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice","volume":"9","author":"I Hauber","year":"2013","journal-title":"PLoS Pathog"},{"key":"ref216","doi-asserted-by":"crossref","first-page":"11461","DOI":"10.1073\/pnas.1405186111","article-title":"RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection","volume":"111","author":"W Hu","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref217","first-page":"6","article-title":"Update of the drug resistance mutations in HIV-1: March 2013","volume":"21","author":"VA Johnson","year":"2013","journal-title":"Top Antivir Med"},{"key":"ref218","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/humrep\/deh806","article-title":"Secretion of cytokines and chemokines by polarized human epithelial cells from the female reproductive tract","volume":"20","author":"JV Fahey","year":"2005","journal-title":"Hum Reprod"},{"key":"ref219","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1095\/biolreprod53.3.488","article-title":"Polymeric immunoglobin (Ig) receptor production and IgA transcytosis in polarized primary cultures of mature rat uterine epithelial cells","volume":"53","author":"JM Richardson","year":"1995","journal-title":"Biol Reprod"},{"key":"ref220","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s11095-005-9258-5","article-title":"Transport kinetics of iron chelators and their chelates in Caco-2 cells","volume":"23","author":"XP Huang","year":"2006","journal-title":"Pharm Res"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/infdis\/173.6.1354","article-title":"Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group","volume":"173","author":"RT Schooley","year":"1996","journal-title":"J Infect Dis"},{"key":"ref222","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/514248","article-title":"Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team","volume":"177","author":"SA Fiscus","year":"1998","journal-title":"J Infect Dis"},{"key":"ref223","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1086\/314638","article-title":"Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children","volume":"179","author":"PE Palumbo","year":"1999","journal-title":"J Infect Dis"},{"key":"ref224","unstructured":"The Health Professsions Council of South Africa, Government of the Republic of South Africa (2008) Guidelines for good practice in the health care professions. Seeking Patients' Informed Consent. pp. 1\u201318. Available at: http:\/\/www.hpcsa.co.za\/downloads\/conduct_ethics\/rules\/generic_ethical_rules\/booklet_9_informed_consent.pdf<\/ext-link>"},{"key":"ref225","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2009-03-209965","article-title":"Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells","volume":"114","author":"Y Eberhard","year":"2009","journal-title":"Blood"},{"key":"ref226","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1359-6446(03)02781-8","article-title":"Medicinal chemistry of target family-directed masterkeys","volume":"8","author":"G M\u00fcller","year":"2003","journal-title":"Drug Discov Today"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0154842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T12:50:44Z","timestamp":1718542244000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0154842"}},"subtitle":[],"editor":[{"given":"Sarah L","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,18]]},"references-count":226,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0154842","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,18]]}}}